Health Condition 1: R196- Halitosis
Conditions
Interventions
Intervention1: Probiotic tablets: Dose: 1 tablet (Minna No Zendamakin WB21 Tablet
Wakamoto Pharmaceutical Co, Tokyo, Japan) containing 6.7 x 108 colony-forming units of L salivarius WB21 and 280 mg of xylitol per tablet.
Route of administration: Oral
Frequency: 3 times a day
Durati
Sponsors
JSS Academy of Higher Education and Research
Dr Nao Suzuki
Eligibility
Inclusion criteria
Inclusion criteria: Willing to participate in the study More than 18 years of age Having oral malodor above a questionable level (OLT � 1.5) Not currently visiting a dentist for treatment Having one or more 3- to 6-mm periodontal pocket depth (PPD) that bleed on probing (BOP) Dentulous Having no daily smoking habit Having no adverse reactions to lactose or fermented milk products. Not using antibiotics within 3 months
Exclusion criteria
Exclusion criteria: Having acute symptoms requiring immediate oral cavity treatment Wearing prostheses Using probiotic supplements Having systemic illness
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| oral halitosis, tongue coating and plaque formation.Timepoint: Baseline and 14 days following intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| Probing pocket depth (PPD) Bleeding on probing Plaque score Tongue coatingTimepoint: Baseline and 14 days following intervention. | — |
Countries
India
Contacts
Public ContactDr Chandrashekar BR
JSS Dental College and Hospital, JSS Academy of Higher Education and Research, Mysuru.
Outcome results
None listed